An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)

#1697

Introduction: Patients (pts) with advanced neuroendocrine tumors (NETs) who have failed sunitinib or everolimus have limited treatment options. Sulfatinib, a novel kinase inhibitor targeting tumor angiogenesis and immune evasion, has shown encouraging anti-tumor activity in patients with advanced NETs in a phase I study.

Aim(s): This is an open-label, single-arm study to further assess the efficacy and safety of sulfatinib in pts with advanced grade 1 or 2 NETs.

Materials and methods: Sulfatinib was orally given 300 mg, qd, until disease progression or unacceptable toxicity. Tumor responses were assessed using RECIST v 1.1.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Xu J, Li J, Bai C, Xu N, Zhou Z,

Keywords: sulfatinib, net, orr, pfs,